Skip to main content
Publications
Herring W, Zhang Y, Pearson I, Tempest M, Freudensprung U, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase registry: comparing natalizumab to fingolimod in patients with inadequate response to disease modifying therapies in relapsing-remitting multiple sclerosis in Scotland. Poster presented at the 7th Joint ECTRIMS-ACTRIMS Meeting; October 26, 2017. Paris, France.